Insmed Q3 2026 slides: BRINSUPRI hits blockbuster status
Insmed Inc. (INSM) reported Q3 2026 revenues of $524.4M, driven by BRINSUPRI's $400.1M (29% sequential growth) and ARIKAYCE's $124.4M. BRINSUPRI reached blockbuster status, raising full-year guidance to $1.35B-$1.4B. The stock rose 11.1% to $107.75 despite a $0.46 adjusted loss per share.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise drove an 11% stock jump, indicating strong market reaction.
Market read
Earnings surprise and guidance lift make INSM a near‑term trade candidate with upside potential.
What to watch
Potential reimbursement challenges in international markets and competition from other respiratory therapies.
Background
Insmed reported its Q3 2026 results, emphasizing blockbuster status for its new bronchiectasis drug and raising full‑year guidance.
Ticker impact
Q3 2026 earnings posted $524.4M revenue, 11.1% stock surge to $107.75 and raised full‑year guidance to $1.35‑$1.40B, marking blockbuster status for BRINSUPRI.
likely upward pressure as investors price in higher revenue outlook and blockbuster launch momentum
The earnings beat, revenue growth, and guidance raise are fresh, material facts that drove an 11% move; market typically rewards such biotech milestones.
Market effects
Boosts outlook for respiratory biotech and specialty pharma sector, may lift peers with similar pipelines.
Positive impact on US biotech indices; Japan market may see related gains as BRINSUPRI launches there.
Highlights growing demand for bronchiectasis treatments worldwide, could influence global specialty drug investors.
Counterpoint
The rapid revenue ramp may be unsustainable; high guidance could be revised down if launch momentum stalls.
Key entities
- companyInsmed Incorporated
US‑listed biotech company (NASDAQ:INSM) reporting Q3 2026 earnings.



